Tenderwize
Back to tender search

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ustekinumab (ATC-Code: L04AC05).

AOK Niedersachsen. Die Gesundheitskasse.Hannover, GermanyNot disclosed712 days leftopen
Sign up to save
50

Opportunity Score

Confidence: 60%

Complexity: low

712 days

Deadline

supplies

Contract

Framework

Deep Portfolio Analysis

  • Company fit score
  • Missing certificates
  • Eligibility blockers
  • Bid / No-Bid recommendation
Create account for AI analysis

AI Analysis Summary

Moderate opportunity

This is an open-house non-exclusive rebate agreement for the pharmaceutical active ingredient Ustekinumab (ATC L04AC05) offered by AOK Niedersachsen. The agreement runs from 01.08.2026 to 31.07.2028, with rolling entry possible on the first of each month. No selection decision is made – all eligible pharmaceutical entrepreneurs may join on identical terms. The notice is published for transparency but is not a public procurement under EU directives. The agreement may be replaced by exclusive rebate contracts at any time, leading to automatic termination.

Strengths

Open procedure

Low complexity

712 days left

Risks

No procurement documents available

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG (or a consortium of such entrepreneurs).
  • Pharmaceutical entrepreneur must have its seat in Germany, EU, or EEA (per § 9 Abs. 2 AMG).
  • Local representatives only eligible if they themselves are pharmaceutical entrepreneurs for the offered drugs.

Buyer

Name

AOK Niedersachsen. Die Gesundheitskasse.

Location

Hannover, DEU

Identifier

AOK- Niedersachsen. Die Gesundheitskasse

Lots (1)

#LOT-0000Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ustekinumab (ATC-Code: L04AC05) innerhalb des Zeitraumes vom 01.08.2026 bis zum 31.07.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

Open-house rebate agreement for Ustekinumab. All eligible pharmaceutical entrepreneurs may join without selection. Uniform terms, no negotiation, maximum duration 24 months, contracts end at latest 31.07.2028. Early termination possible if exclusive contracts come into effect.

33600000DEU

Procurement Details

Publication

14 Jun 2026

Deadline

27 May 2028, 11:00

Procedure

open

Contract

supplies

Language

DEU

Publication #

407882-2026

Classification

Pharmaceutical products

Performance: Germany

Pharmaceutical products Tender in Germany | TED 407882-2026